JP2011517659A5 - - Google Patents

Download PDF

Info

Publication number
JP2011517659A5
JP2011517659A5 JP2010542274A JP2010542274A JP2011517659A5 JP 2011517659 A5 JP2011517659 A5 JP 2011517659A5 JP 2010542274 A JP2010542274 A JP 2010542274A JP 2010542274 A JP2010542274 A JP 2010542274A JP 2011517659 A5 JP2011517659 A5 JP 2011517659A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutical composition
corneal
inhibits
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010542274A
Other languages
English (en)
Japanese (ja)
Other versions
JP5886523B2 (ja
JP2011517659A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/000114 external-priority patent/WO2009089036A2/en
Publication of JP2011517659A publication Critical patent/JP2011517659A/ja
Publication of JP2011517659A5 publication Critical patent/JP2011517659A5/ja
Application granted granted Critical
Publication of JP5886523B2 publication Critical patent/JP5886523B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010542274A 2008-01-09 2009-01-09 眼の炎症性障害を処置するための治療組成物 Active JP5886523B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1056608P 2008-01-09 2008-01-09
US61/010,566 2008-01-09
PCT/US2009/000114 WO2009089036A2 (en) 2008-01-09 2009-01-09 Therapeutic compositions for treatment of ocular inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2011517659A JP2011517659A (ja) 2011-06-16
JP2011517659A5 true JP2011517659A5 (cg-RX-API-DMAC7.html) 2012-02-23
JP5886523B2 JP5886523B2 (ja) 2016-03-16

Family

ID=40853700

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010542274A Active JP5886523B2 (ja) 2008-01-09 2009-01-09 眼の炎症性障害を処置するための治療組成物

Country Status (6)

Country Link
US (3) US9309313B2 (cg-RX-API-DMAC7.html)
EP (1) EP2242504B1 (cg-RX-API-DMAC7.html)
JP (1) JP5886523B2 (cg-RX-API-DMAC7.html)
AU (1) AU2009204441B2 (cg-RX-API-DMAC7.html)
CA (2) CA2711696C (cg-RX-API-DMAC7.html)
WO (1) WO2009089036A2 (cg-RX-API-DMAC7.html)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2187900B1 (en) * 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
US20110223169A1 (en) * 2008-11-26 2011-09-15 Stern Michael E Il-17 antibody inhibitor for treating dry eye
EP2385839B1 (en) 2009-01-09 2014-11-26 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
US20110038871A1 (en) * 2009-08-11 2011-02-17 Veena Viswanth Ccr2 inhibitors for treating conditions of the eye
EP2473523A2 (en) * 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US9011861B2 (en) 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
RU2585491C2 (ru) 2010-06-04 2016-05-27 Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем Регуляция метаболизма с помощью mir-378
US20120004298A1 (en) * 2010-06-30 2012-01-05 Hassan Chaouk Ophthalmic devices containing chemokine antagonists
HRP20230776T1 (hr) 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
WO2012148547A1 (en) * 2011-02-24 2012-11-01 The Schepens Eye Research Institute, Inc. Compositions and methods for treating inflammatory conditions of the ocular surface
US10451897B2 (en) 2011-03-18 2019-10-22 Johnson & Johnson Vision Care, Inc. Components with multiple energization elements for biomedical devices
US9812730B2 (en) 2011-08-02 2017-11-07 Johnson & Johnson Vision Care, Inc. Biocompatible wire battery
US8857983B2 (en) 2012-01-26 2014-10-14 Johnson & Johnson Vision Care, Inc. Ophthalmic lens assembly having an integrated antenna structure
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
WO2014093870A2 (en) * 2012-12-13 2014-06-19 The Schepens Eye Research Institute, Inc. Use of c-c chemokine receptor type 7 (ccr7) inhibitors
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
TWI623313B (zh) * 2013-03-13 2018-05-11 Santen Pharmaceutical Co Ltd 瞼板腺功能障礙之治療劑
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ, インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
US9383593B2 (en) 2014-08-21 2016-07-05 Johnson & Johnson Vision Care, Inc. Methods to form biocompatible energization elements for biomedical devices comprising laminates and placed separators
US10361405B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes
US9793536B2 (en) 2014-08-21 2017-10-17 Johnson & Johnson Vision Care, Inc. Pellet form cathode for use in a biocompatible battery
US10381687B2 (en) 2014-08-21 2019-08-13 Johnson & Johnson Vision Care, Inc. Methods of forming biocompatible rechargable energization elements for biomedical devices
US10361404B2 (en) 2014-08-21 2019-07-23 Johnson & Johnson Vision Care, Inc. Anodes for use in biocompatible energization elements
US9715130B2 (en) 2014-08-21 2017-07-25 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form separators for biocompatible energization elements for biomedical devices
US10627651B2 (en) 2014-08-21 2020-04-21 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization primary elements for biomedical devices with electroless sealing layers
US9941547B2 (en) 2014-08-21 2018-04-10 Johnson & Johnson Vision Care, Inc. Biomedical energization elements with polymer electrolytes and cavity structures
US9599842B2 (en) 2014-08-21 2017-03-21 Johnson & Johnson Vision Care, Inc. Device and methods for sealing and encapsulation for biocompatible energization elements
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR101812611B1 (ko) 2015-04-24 2017-12-28 포항공과대학교 산학협력단 스마트 콘택트 렌즈 및 스마트 안경
US10816823B2 (en) * 2015-05-04 2020-10-27 École Polytechnique Fédérale de Lausanne Ophthalmic contact lens with compressible affinity matrix
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
WO2017120479A1 (en) 2016-01-07 2017-07-13 The Schepens Eye Research Institute, Inc. Therapeutics for ocular immunoinflammatory diseases
US10345620B2 (en) 2016-02-18 2019-07-09 Johnson & Johnson Vision Care, Inc. Methods and apparatus to form biocompatible energization elements incorporating fuel cells for biomedical devices
EP3490542A4 (en) * 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
MX381639B (es) 2016-12-23 2025-03-13 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
CA3088957A1 (en) * 2017-01-17 2018-07-26 Tufts Medical Center, Inc. Adoptive transfer of plasmacytoid dendritic cells to prevent or treat ocular diseases and conditions
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CN111601799B (zh) 2018-01-15 2023-06-09 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物
US11619832B2 (en) * 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
JP2021516966A (ja) * 2018-03-09 2021-07-15 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織への生物学的薬物の送達
JP7855312B2 (ja) 2018-04-27 2026-05-08 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
WO2020011731A1 (en) 2018-07-12 2020-01-16 UCB Biopharma SRL Spirocyclic indane analogues as il-17 modulators
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CN114449999A (zh) 2019-09-06 2022-05-06 诺瓦利克有限责任公司 用于治疗葡萄膜炎的眼用组合物
JP7667142B2 (ja) * 2019-09-30 2025-04-22 ヤンセン ファーマシューティカ エヌ.ベー. 大分子モジュレータを用いたil-17標的結合アッセイのための組成物及び方法
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021191689A2 (en) * 2020-03-05 2021-09-30 Yuyu Pharma, Inc. Treatment of inflammatory diseases with peptides and pharmaceutical compositions
CN115702024A (zh) 2020-04-07 2023-02-14 Ucb生物制药有限责任公司 用作il-17调节剂的二氟环己基衍生物
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
MX2022014925A (es) 2020-05-27 2023-01-04 Sanofi Sa Moduladores de il-17a.
EP4157828A1 (en) 2020-05-27 2023-04-05 Sanofi Il-17a modulators
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
WO2022006076A1 (en) * 2020-07-01 2022-01-06 The Johns Hopkins University Ocular treatment compositions and methods
WO2022061132A1 (en) * 2020-09-17 2022-03-24 The Regents Of The University Of Colorado, A Body Corporate Ophthalmic devices for the treatment or amelioration of dry eye disease, and related methods of use
WO2022096412A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
WO2022096411A1 (en) 2020-11-09 2022-05-12 UCB Biopharma SRL Dicyclopropylmethyl derivatives as il-17 modulators
US20240140951A1 (en) 2020-12-14 2024-05-02 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
AR126255A1 (es) 2021-07-01 2023-10-04 UCB Biopharma SRL Derivados de imidazotriazina como moduladores de il-17
WO2023215269A1 (en) * 2022-05-06 2023-11-09 The Regents Of The University Of California Lacripep promotes neuroregeneration and maintains epithelial progenitor cell identity
EP4536189A4 (en) * 2022-06-08 2026-07-29 The Schepens Eye Research Inst Inc METHODS OF TREATING DRY EYE DISEASE
GB202210731D0 (en) 2022-07-22 2022-09-07 UCB Biopharma SRL Therapeutic agents
WO2024102746A1 (en) * 2022-11-08 2024-05-16 Microcures, Inc. Methods and agents for treating neurotrophic keratitis
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
JP2026500183A (ja) 2022-12-09 2026-01-06 サノフイ 治療用化合物
WO2024126249A1 (en) 2022-12-14 2024-06-20 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators
GB202218860D0 (en) 2022-12-14 2023-01-25 Ucb Biopharma Sprl Therapeutic agents
GB202218846D0 (en) 2022-12-14 2023-01-25 UCB Biopharma SRL Therapeutic agents
GB202305587D0 (en) 2023-04-17 2023-05-31 UCB Biopharma SRL Therapeutic agents
GB202305585D0 (en) 2023-04-17 2023-05-31 UCB Biopharma SRL Therapeutic agents
WO2025104230A1 (en) 2023-11-17 2025-05-22 Sanofi Benzoxazoles as modulators of il-17a
WO2025248073A1 (en) 2024-05-30 2025-12-04 Sanofi Therapeutic compounds
WO2026073936A1 (en) 2024-10-02 2026-04-09 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators
WO2026073929A1 (en) 2024-10-02 2026-04-09 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators
WO2026073937A1 (en) 2024-10-02 2026-04-09 UCB Biopharma SRL Imidazotriazine derivatives as il-17 modulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022130A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
WO2004042024A2 (en) 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
EP1765865A2 (en) * 2004-06-10 2007-03-28 ZymoGenetics, Inc. Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
US20070265341A1 (en) * 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
ME02705B (me) * 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
DE602006009834D1 (de) * 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
EP1968594B1 (en) 2005-11-29 2010-09-29 GlaxoSmithKline LLC Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema
CN101489569A (zh) * 2006-06-12 2009-07-22 席拉坎有限责任公司 眼表面疾病的局部治疗
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders

Similar Documents

Publication Publication Date Title
JP5886523B2 (ja) 眼の炎症性障害を処置するための治療組成物
EP2385839B1 (en) Therapeutic compositions for treatment of corneal disorders
JP2012515164A5 (cg-RX-API-DMAC7.html)
US20230348534A1 (en) Sap and peptidomimetics for treatment of eye disease
JP2025029084A (ja) 角結膜のホメオスタシスを確立、回復及び維持するための方法
US20210299219A1 (en) Compositions and methods for prevention and treatment of corneal haze and scarring
Marsovszky et al. Confocal Microscopy of Epithelial and Langerhans Cells of the Cornea in Patients Using Travoprost Drops Containing Two Different Preservatives: L. Marsovszky et al.
US20250276004A1 (en) High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
CA2630193A1 (en) Pharmaceutical composition free from dexpanthenol, calcium ions, and phosphate, and use of calcium chelating agent and ophthalmologically compatible viscosity regulator
JP7291459B2 (ja) 動体視力および高次収差を改善するためのprg4の使用
JP2022542889A (ja) ドライアイ疾患のためのtsg6ポリペプチドフラグメント
Kim et al. Effects of chondrocyte-derived extracellular matrix in a dry eye mouse model
Chung et al. Effects of exogenous recombinant human bone morphogenic protein-7 on the corneal epithelial mesenchymal transition and fibrosis
Meng et al. Basement membrane regeneration and TGF-β1 expression in rabbits with corneal perforating injury
Zhang et al. The RPE in myopia development
US20250312412A1 (en) Methods for treating dry eye disease
Meek et al. Corneal stroma: collagen ultrastructure and orientation in health and disease
ES3056786T3 (en) Methods and compositions for reducing corneal endothelial cell loss
Petropoulos et al. Corneal Nerves: Useful for Ophthalmology But Indispensable for Neurology
Kučinskaitė et al. SAUSŲ AKIŲ SINDROMAS PO LASIK REFRAKCIJOS KOREKCIJOS OPERACIJOS IR JO GYDYMAS
Wu Neuroregenerative and anti-inflammatory effects of decorin on the injured cornea
AU2014227534A1 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
Tananakina—ophthalmologist Zenlens scleral lenses for visual rehabilitation of patients with irregular cornea: a usage experience OO Alyaeva—Cand. Med. Sci., ophthalmologist, head of the scientific research department OI Ryabenko—ophthalmologist, chief physician